142 related articles for article (PubMed ID: 32068648)
1. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
[TBL] [Abstract][Full Text] [Related]
2. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
Horiuchi M; Yoshida M; Yamasaki K; Sakagami R; Aoyama T; Tatsumi N; Tsutsumi M; Nakaya Y; Fuseya H; Yoshimura T; Hayashi Y; Nakao T; Yamane T
Ann Hematol; 2021 May; 100(5):1329-1331. PubMed ID: 33150465
[No Abstract] [Full Text] [Related]
4. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
5. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
6. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
[No Abstract] [Full Text] [Related]
8. Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.
Heilmann AM; Schrock AB; He J; Nahas M; Curran K; Shukla N; Cramer S; Draper L; Verma A; Erlich R; Ross J; Stephens P; Miller VA; Ali SM; Verglio JA; Tallman MS; Mughal TI
Leukemia; 2017 Sep; 31(9):1989-1992. PubMed ID: 28552906
[No Abstract] [Full Text] [Related]
9. Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with
Aldoss I; Pullarkat V
Leuk Lymphoma; 2019 Nov; 60(11):2832-2834. PubMed ID: 31014138
[No Abstract] [Full Text] [Related]
10. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
[TBL] [Abstract][Full Text] [Related]
11. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
13. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
14. [Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review].
Chen YQ; Zheng YZ; Li J; Hua XL; Le SH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):69-71. PubMed ID: 36987727
[No Abstract] [Full Text] [Related]
15. Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Perwein T; Strehl S; König M; Lackner H; Panzer-Grümayer R; Mann G; Attarbaschi A; Urban EC; Haas OA
Haematologica; 2016 Aug; 101(8):e332-5. PubMed ID: 27125982
[No Abstract] [Full Text] [Related]
16. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Ishihara T; Watakabe M; Ochi S; Akisada N; Nogami K
Pediatr Int; 2022 Jan; 64(1):e14955. PubMed ID: 35289450
[No Abstract] [Full Text] [Related]
18. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
[No Abstract] [Full Text] [Related]
19. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
20. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
